drugset / Trial / NCT05736107
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing subcutaneous fat.
Timeline
- Start
- 2023-05-30
- Primary completion
- 2024-05-20
- Completion
- 2024-05-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBL-514 | Unknown | 2 unknown | Subcutaneous |
Indications
No indication recorded.